Results 281 to 290 of about 354,322 (345)

If treating obesity with GLP‐1‐based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials

Diabetes, Obesity and Metabolism, EarlyView.
Anastasios Tentolouris, Ioannis Ntanasis‐Stathopoulos   +1 more
wiley   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

MULTIPLE MYELOMA

Annals of Surgery, 1931
openaire   +3 more sources

Hematopathology Practice in the Digital Era: What has Changed?

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Hematopathology workflows are complex, since they include numerous data points necessary for guiding further testing, diagnosis, and patient management. The workflows start with complete blood cell counts, with subsequent morphologic evaluation of peripheral blood (PB) and bone marrow (BM).
Olga Pozdnyakova
wiley   +1 more source

Identification of Potential Ferroptosis Biomarkers in Multiple Myeloma via WGCNA and Experiments. [PDF]

Cancer Rep (Hoboken)
Wang Y, Xie X, Gu M, Zheng Y, Wu J, Wang Q, Ling Z, Li R.   +7 more
europepmc   +1 more source

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

Journal of Internal Medicine, EarlyView.
Abstract Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients.
Holly J. Kramer, George L. Bakris
wiley   +1 more source

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.

Blood
Dutta D, Liu J, Wen K, Ray A, Salatino A, Liu X, Gulla A, Hideshima T, Song Y, Anderson KC.   +9 more
europepmc   +1 more source

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. [PDF]

Blood Adv
Kowalski A, Lykon J, Diamond B, Coffey D, Kaddoura M, Maura F, Hoffman J, Pandey A, Kazandjian D, Landgren O.   +9 more
europepmc   +1 more source

Trend Analysis of Medically Related Osteonecrosis of the Jaw in the United States Using US National Inpatient Data From 2016 to 2022

Journal of Public Health Dentistry, EarlyView.
ABSTRACT Objectives This study presents a trend analysis of Medication‐Related Osteonecrosis of the Jaw (MRONJ) using US National Inpatient Sample (NIS) data from 2016 to 2022, providing insights into its epidemiology, comorbidities, and economics.
N. Sheshashayee, M. B. Rao, E. Holmes, D. G. Krishnan   +3 more
wiley   +1 more source

Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma. [PDF]

Future Oncol
Martin TG, van de Donk NWCJ, Rodríguez-Otero P, Mateos MV, Kobos R, Chastain K, Doyle M, Nooka AK.   +7 more
europepmc   +1 more source